NCT05969795

Brief Summary

To evaluate whether single euploid embryo transfer in NC without routinely administered LPS is non-inferior to NC with routinely administered LPS.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
342

participants targeted

Target at P75+ for phase_1

Timeline
4mo left

Started Sep 2023

Typical duration for phase_1

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Sep 2023Sep 2026

First Submitted

Initial submission to the registry

July 24, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

September 5, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2026

Expected
Last Updated

January 9, 2025

Status Verified

January 1, 2025

Enrollment Period

2.7 years

First QC Date

July 24, 2023

Last Update Submit

January 8, 2025

Conditions

Keywords

implantation rateinfertilitypregnancy ratenatural cycleluteal phase supportlive birthprogesterone

Outcome Measures

Primary Outcomes (6)

  • Implantation rate

    Number of embryos which have produced ultrasonographic evidence of an intrauterine gestational sac per the total number of embryos transferred into the uterine cavity (Zegers-Hochschild et al., 2009).

    2 months

  • Clinical pregnancy rate

    hCG \> 15 Iu/ml and ultrasound confirmation of a gestational sac

    2 months

  • Live birth rate

    Number of deliveries that resulted in a live born neonate, expressed per 100 embryo transfers (Zegers-Hochschild et al., 2009)

    41 weeks

  • Serum P4 levels on ET day

    Progesterone level on the day of embryo transfer

    1 day

  • Serum E2 and P4 levels on day 5 or 6 after ET procedure

    Estradiol and Progesterone levels on day 5 or 6 after embryo transfer

    6 days

  • Serum E2 and P4 levels on day 10 after ET procedure

    Estradiol and Progesterone levels on day 10 after embryo transfer

    10 days

Study Arms (2)

Study Group

OTHER

Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Blood for P4 measurement will be drawn upon admission to the clinic for the ET procedure. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure.

Diagnostic Test: Transvaginal ultrasoundDiagnostic Test: Serial serum LH, E2, P4Diagnostic Test: Serum P4 day of ET - Study GroupProcedure: Embryo transferDiagnostic Test: Serum hCG 10 days after ETDiagnostic Test: Serum P4 10 days after ET

Control Group

OTHER

Intermittent ultrasound scans to monitor follicular growth and serial measurements of serum LH, E2 and P4 levels throughout the cycle to determine ovulation. Embryo transfer (ET) will be scheduled on the fifth day after ovulation. Administer on FET day 200 mg of P4 and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. Blood for P4 measurement will be drawn before starting LPS in form of vaginal progesterone. P4 will be measured on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy.

Diagnostic Test: Transvaginal ultrasoundDiagnostic Test: Serial serum LH, E2, P4Drug: Progesterone 100 Mg Vaginal InsertDiagnostic Test: Serum P4 day of ET - Control GroupProcedure: Embryo transferDiagnostic Test: Serum hCG 10 days after ETDiagnostic Test: Serum P4 10 days after ET

Interventions

Intermittent transvaginal ultrasound throughout the cycle to monitor follicular growth

Control GroupStudy Group

Serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4 )levels throughout the cycle to determine ovulation. LH-surge is identified when a rise of 180% above the previous level occurred and ovulation is confirmed with a decrease in E2 concentration, and a rise of progesterone level to ≥ 1.0 ng/ml (Irani et al., 2017).

Control GroupStudy Group

On day of ET procedure, to administer 200 mg of vaginal progesterone and increase to 300 mg/day from the day after the ET onwards until the pregnancy test. In case of an implantation, vaginal P4 will be continued until 7 weeks of pregnancy

Also known as: Progesterone 100Mg Vag Tab
Control Group

Serum P4 will be drawn before starting LPS in form of vaginal progesterone on the day of ET procedure

Control Group

Serum P4 will be drawn when study group participants are admitted to the clinic for the ET procedure.

Study Group

The procedure in which embryo is placed in the uterus.

Also known as: ET
Control GroupStudy Group

Pregnancy will be confirmed / excluded by measurement of serum hCG 10 days after ET procedure and a level of \> 15 IU will be regarded as positive result. The definitions of biochemical, ectopic, clinical and ongoing pregnancy follow the ICMART criteria (Zegers-Hochschild, 2006)

Control GroupStudy Group

Serum P4 will be drawn on day 5 or day 6 after the ET procedure and together with the hCG 10 days after ET procedure

Control GroupStudy Group

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18 to 40 years
  • Regular ovulatory cycles
  • Availability of at least one euploid embryo after Trophectoderm biopsy for PGT-A on day 5 or day 6
  • Detection of ovulation by P4 rise \> 1.0 ng/ml after LH surge
  • P4 value of at least 5 ng/ml on day 4 after ovulation

You may not qualify if:

  • History of repeated pre-menstrual spotting
  • Factors affecting the implantation through anatomical changes of the uterus / ovaries or the tubes (adenomyosis, Asherman syndrome, endometriosis, uterine fibroids / polyps, isthmocele with intracavitary fluid presence, hydrosalpinx….)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

ART Fertility Clinics LLC

Abu Dhabi, 60202, United Arab Emirates

RECRUITING

ART Fertility Clinics Al Ain

Al Ain City, United Arab Emirates

RECRUITING

ART Fertility Clinics Dubai

Dubai, United Arab Emirates

NOT YET RECRUITING

Related Publications (10)

  • Bortoletto P, Prabhu M, Baker VL. Association between programmed frozen embryo transfer and hypertensive disorders of pregnancy. Fertil Steril. 2022 Nov;118(5):839-848. doi: 10.1016/j.fertnstert.2022.07.025. Epub 2022 Sep 25.

    PMID: 36171152BACKGROUND
  • Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv. 1978 Feb;33(2):69-81. doi: 10.1097/00006254-197802000-00001. No abstract available.

    PMID: 341008BACKGROUND
  • Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest. 1984 Jun;73(6):1638-47. doi: 10.1172/JCI111370.

    PMID: 6427277BACKGROUND
  • Ginstrom Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol. 2019 Aug;221(2):126.e1-126.e18. doi: 10.1016/j.ajog.2019.03.010. Epub 2019 Mar 22.

    PMID: 30910545BACKGROUND
  • Pape J, Levy J, von Wolff M. Early pregnancy complications after frozen-thawed embryo transfer in different cycle regimens: A retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2022 Dec;279:102-106. doi: 10.1016/j.ejogrb.2022.10.015. Epub 2022 Oct 21.

    PMID: 36308939BACKGROUND
  • Roelens C, Blockeel C. Impact of different endometrial preparation protocols before frozen embryo transfer on pregnancy outcomes: a review. Fertil Steril. 2022 Nov;118(5):820-827. doi: 10.1016/j.fertnstert.2022.09.003.

    PMID: 36273850BACKGROUND
  • Soules MR, Clifton DK, Steiner RA, Cohen NL, Bremner WJ. The corpus luteum: determinants of progesterone secretion in the normal menstrual cycle. Obstet Gynecol. 1988 May;71(5):659-66.

    PMID: 3357651BACKGROUND
  • Su S, Zeng M, Duan J. Luteal phase support for natural cycle frozen embryo transfer: a meta-analysis. Gynecol Endocrinol. 2022 Feb;38(2):116-123. doi: 10.1080/09513590.2021.1998438. Epub 2021 Nov 3.

    PMID: 34730071BACKGROUND
  • Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2012 Nov;98(5):1112-7. doi: 10.1016/j.fertnstert.2012.06.050. Epub 2012 Jul 20.

    PMID: 22819186BACKGROUND
  • von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043.

    PMID: 30636552BACKGROUND

Related Links

MeSH Terms

Conditions

Infertility, FemaleInfertility

Interventions

ProgesteroneEmbryo Transfer

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsCorpus Luteum HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsProgesterone CongenersGonadal Steroid HormonesReproductive Techniques, AssistedReproductive TechniquesTherapeuticsInvestigative Techniques

Study Officials

  • Barbara Lawrenz, PhD

    ART Fertility Clinics LLC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Scientific Director

Study Record Dates

First Submitted

July 24, 2023

First Posted

August 1, 2023

Study Start

September 5, 2023

Primary Completion

April 30, 2026

Study Completion (Estimated)

September 30, 2026

Last Updated

January 9, 2025

Record last verified: 2025-01

Locations